Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EXOZYMES INC.
Report date April 01, 2026 · Filed April 08, 2026
Section 16 reporting ended · disclosed 2026-04-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 645,149 |
Reported balance
After 2026-04-01 transaction · row 1
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 3,999 · Balance 645,149 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2026 Filed Apr 8, 2026 10:23 UTC | EXOZYMES INC. EXOZ · Entity 1147 | GrantCOMMON STOCK | 3,999 | $8.44 | $33,751.56 |
DisclosureSEC source: 0001493152-26-015627 · ownership.xml · nonDerivative · entry 1 Opgenorth Paul Hideo · CIK 0002033517 · Vice President, Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 645,149 Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 21:19 UTC | EXOZYMES INC. EXOZ · Entity 1147 | GrantCommon Stock | 2,990 | $12.54 | $37,494.60 |
DisclosureSEC source: 0001641172-25-015458 · ownership.xml · nonDerivative · entry 1 Opgenorth Paul Hideo · CIK 0002033517 · Vice President, Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 641,150 Read SEC document |
| November 08, 2024 Filed Nov 19, 2024 00:54 UTC | EXOZYMES INC. IZTC · Entity 1147 | ConversionCommon Stock | 2,344 | $6.40 | $15,001.60 |
DisclosureSEC source: 0001493152-24-046629 · ownership.xml · nonDerivative · entry 1 Opgenorth Paul Hideo · CIK 0002033517 · Vice President, Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 640,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.